Progestin News and Research

RSS

Brisdelle receives FDA approval to treat hot flashes associated with menopause

The U.S. Food and Drug Administration today approved Brisdelle (paroxetine) to treat moderate to severe hot flashes (vasomotor symptoms) associated with menopause. Brisdelle, which contains the selective serotonin reuptake inhibitor paroxetine mesylate, is currently the only non-hormonal treatment for hot flashes approved by the FDA.

29 Jun 2013

Study shows hormonal therapy increases risk of breast cancer

The study Dr. Chlebowski authored reported that estrogen plus progestin use is linked with increased breast cancer incidence. In addition, it said the prognosis is similar for both users and nonusers of combined hormone therapy, suggesting that mortality from breast cancer may be higher for hormone therapy users as well.

30 Mar 2013

FDA approves Teva's Quartette tablets for prevention of pregnancy

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has approved Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets for the prevention of pregnancy.

30 Mar 2013

Study: Hormone-therapy-related breast cancer cells can be attacked by cancer therapies

More than 100 women per day die from breast cancer in the United States. The odds of developing breast cancer increase for women taking hormone replacement therapy to avoid the effects of menopause.

28 Mar 2013

Women over 40 need to be vigilant about contraception even in perimenopause

Women reaching the age of 40 tend to be less vigilant about birth control because they think the risk of pregnancy is low - or that birth control can cause health problems - but a review of the evidence by a team that includes a Women & Infants Hospital of Rhode Island physician recently underscored the need to be vigilant about contraception even in perimenopause.

26 Mar 2013

Study finds that some younger women see both benefit and harm from annual exams

Screening for breast cancer every two years appears just as beneficial as yearly mammograms for women ages 50 to 74, with significantly fewer "false positives" - even for women whose breasts are dense or who use hormone therapy for menopause.

20 Mar 2013

Long-acting reversible contraception with progestin may increase risk of type 2 diabetes in women

A first-of-its-kind study by researchers at the Keck School of Medicine of the University of Southern California (USC) indicates that healthy, obese, reproductive-age women who use long-acting reversible contraception (LARC) containing the hormone progestin have a slightly increased risk for developing type 2 diabetes when compared to those who use non-hormonal contraception.

11 Feb 2013

TSEC strategy can benefit postmenopausal women

Investigators at Wake Forest Baptist Medical Center have concluded research on a new postmenopausal hormone therapy that shows promise as an effective treatment for menopausal symptoms and the prevention of osteoporosis without increasing the risk for heart disease or breast cancer.

13 Dec 2012

Clinical hypnosis can effectively reduce hot flashes among postmenopausal women

Clinical hypnosis can effectively reduce hot flashes and associated symptoms among postmenopausal women, according to a new study conducted by researchers at Baylor University's Mind-Body Medicine Research Laboratory.

1 Nov 2012

Austrian researchers receive $7.4 million award to verify new breast cancer pathways

The innovator's award recognises Josef Penninger's work in identifying a key molecular pathway how hormone replacement therapies and contraceptive pills can lead to breast cancer. His team provided the first genetic proof that a protein called RANKL is the master regulator of bone loss, which has contributed to the development of a novel drug already approved for the treatment of osteoporosis and skeletal related events in multiple cancers.

23 Oct 2012

Drospirenone-containing birth control pills associated with increased risk of blood clots

A U.S. Food and Drug Administration-funded study led by the Kaiser Permanente Northern California Division of Research found an increased risk of arterial thrombotic events (ATE) and venous thromboembolic events (VTE) - commonly referred to as blockage of arteries and blood clots, respectively - associated with drospirenone-containing birth control pills compared to four low-dose estrogen combined hormonal contraceptives.

20 Oct 2012

Breast-feeding associated with reduced risk of ER/PR-negative breast cancer

Breast-feeding reduces the risk for estrogen receptor-negative and progesterone receptor-negative breast cancer, according to a study conducted at Columbia University's Mailman School of Public Health.

19 Oct 2012

Transvaginal ultrasound effective in treating early-stage endometrial cancer

A common birth control device is effective in treating early-stage endometrial cancer in morbidly obese and high-risk surgery patients, said Georgia Health Sciences University Cancer Center researchers, and could lead to a cost-effective treatment for all women with this cancer type.

17 Oct 2012

GAPPS announces five new projects for prevention of preterm births

Five innovative research projects aiming to prevent premature birth were announced today by the Global Alliance to Prevent Prematurity and Stillbirth (GAPPS), an initiative of Seattle Children's.

16 Oct 2012

Marijuana and testicular cancer: an interview with Victoria Cortessis

This is a set of malignancies that arise in germ cells of the testicles, the specialized cells that produce sperm. Taken together, testicular cancers are the most common form of malignancy that occurs in young men (approximately 15 to 35 years of age).

24 Sep 2012

Research roundup: Readmission risks after surgery; Assessing Medicaid applicants' eligibility; Satisfaction among health plan types

General Surgeons Identify Postoperative Complications Posing Strongest Readmission Risks -- Researchers found that about 11 percent of patients in a study of 1,442 individuals who underwent general surgery were readmitted to the hospital within 30 days.

31 Aug 2012

FDA approves Watson's ANDA for Next Choice ONE DOSE emergency contraceptive

Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Next Choice ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step. Watson plans to launch the product immediately.

13 Jul 2012

Male hormonal contraceptives applied daily to the skin reduce sperm production

Male hormonal contraceptives applied daily to the skin reduce sperm production, finds a new study to be presented Sunday at The Endocrine Society's 94th Annual Meeting in Houston.

26 Jun 2012

Apigenin effective against human breast cancer

Apigenin, a natural substance found in grocery store produce aisles, shows promise as a non-toxic treatment for an aggressive form of human breast cancer, following a new study at the University of Missouri.

17 May 2012

Endocrine Society and its Hormone Health Network release ‘Menopause Map’

Women going through menopause now have a first-of-its-kind interactive guide to help them better understand their menu of treatment options, including whether hormone therapy may be right for them. The Endocrine Society and its Hormone Health Network today released the "Menopause Map," an online tool to help women and their doctors discuss which hormonal and non-hormonal treatment options would be most effective and safe to relieve the sometimes debilitating symptoms of menopause.

2 May 2012